Clinical Trials

Takeda Pharmaceutical Company Limited and PvP Biologics, Inc. announced a global agreement for the development of KumaMax, a novel enzyme designed to break down the immune-reactive…
Read More...

PTC Therapeutics, Inc. announced that its joint development program in Spinal Muscular Atrophy (SMA) with Roche and the SMA Foundation (SMAF) initiated a clinical study in infants with…
Read More...

Custopharm, Inc., a U.S. leader in generic injectable products, announced that it has acquired two paragraph IV abbreviated new drug application (ANDA) products from Perrigo Company…
Read More...

Senhwa Biosciences, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to CX-4945 for the treatment of cholangiocarcinoma. CX-4945 is…
Read More...

Yisheng Biopharma Co., Ltd., a biopharmaceutical company focusing on research, development, manufacturing, sales and marketing of immuno-therapeutic products and vaccines, today…
Read More...

Dermira, Inc., a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated therapies to improve the lives of patients with…
Read More...

Marinus Pharmaceuticals, Inc., a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today announced that…
Read More...

Drug firm Lupin has received final approval from the US health regulator to market cevimeline hydrochloride capsules, used for treatment of symptoms of dry mouth in patients with…
Read More...

Suven Life Sciences Ltd announces that the grant of one (1) product patent from Eurasia (025136) and one (1) product patent from Norway (339034) corresponding to the New Chemical…
Read More...

Sanofi and its vaccines global business unit Sanofi Pasteur confirmed today the end of their vaccine joint-venture with MSD (known as Merck & Co. Inc., in the United States and…
Read More...

DNAtrix, a clinical stage biotechnology company developing virus-driven immunotherapies for cancer, announced it has entered into an exclusive license agreement with the University of…
Read More...

DNAtrix, a clinical stage biotechnology company developing virus-driven immunotherapies for cancer, announced that the first patients have been treated in a multicenter Phase 2 trial…
Read More...

Nexus BioPharma has signed an agreement to license TransChem's transition state chemistry technology for kinase inhibition. Kinases are enzymes that regulate essential cellular…
Read More...

Codexis has completed the second and final phase in the transfer of its CodeEvolver protein engineering platform technology to Merck, known as MSD outside the US and Canada, under a…
Read More...

Ligand Pharmaceuticals has entered into a worldwide license agreement with Menlo Park, CA-based TeneoBio. Under the license, TeneoBio will be able to use the OmniFlic technology from…
Read More...

EPAM Systems and Sinequa, a leader in Cognitive Search and Analytics and a founding sponsor of the Cognitive Computing Consortium, today announced a partnership to deliver search and…
Read More...

MilliporeSigma launched a first-of-its-kind gene editing technology to modify CHO cell lines to be resistant to minute virus of mice (MVM), a common contamination threat that remains…
Read More...

Compugen Ltd. disclosed that its LINKS computational platform, initially designed for the characterization and differentiation of existing novel drug target candidates, has been…
Read More...

Veeva Systems announced that Daiichi Sankyo Company, Limited (hereinafter, Daiichi Sankyo) based in Japan, selected Veeva Vault eTMF, Veeva Vault QualityDocs, and Veeva Vault…
Read More...

Eleven Biotherapeutics, a biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, announced the effectiveness of the exclusive licensing…
Read More...